{
    "clinical_study": {
        "@rank": "36724", 
        "acronym": "LIPS-B", 
        "arm_group": [
            {
                "arm_group_label": "budesonide and formoterol", 
                "arm_group_type": "Experimental", 
                "description": "Budesonide and formoterol"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Normal saline, the quantity and appearance same as the intervention arm."
            }
        ], 
        "brief_summary": {
            "textblock": "THE STUDY WILL ANSWER WHETHER INHALED BUDESONIDE AND FORMOTEROL ARE ABLE TO ALLEVIATE OR\n      PREVENT PULMONARY INJURY WHEN ADMINISTERED EARLY IN HOSPITAL COURSE TO THE PATIENTS AT RISK\n      FOR DEVELOPING ARDS"
        }, 
        "brief_title": "LIPS-B: Lung Injury Prevention Study With Budesonide and Beta", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Respiratory Distress Syndrome (ARDS)", 
        "condition_browse": {
            "mesh_term": [
                "Respiratory Distress Syndrome, Newborn", 
                "Respiratory Distress Syndrome, Adult", 
                "Acute Lung Injury", 
                "Lung Injury", 
                "Wounds and Injuries"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients (age > 18);\n\n          -  Admitted to the hospital through the emergency department (ED);\n\n          -  High risk of developing ARDS (Lung Injury Prediction Score-LIPS greater than or equal\n             to four;\n\n          -  New chest radiograph performed on clinical grounds\n\n        Exclusion Criteria:\n\n          -  Inhaled corticosteroid and/or beta agonist treatment on admission or within 7 days\n             prior to admission (history of asthma or COPD necessitating therapy)\n\n          -  Chronic pulmonary disease requiring daytime oxygen supplementation therapy\n\n          -  Systemic steroid treatment on admission or within 7 days prior to admission\n             equivalent to more than 5 mg of prednisone daily\n\n          -  Inability to obtain consent within 12 hours of hospital presentation\n\n          -  Acute lung injury prior to randomization\n\n          -  Receiving mechanical ventilation before current hospital admission (patient who is\n             ventilator dependent)\n\n          -  Presentation believed to be purely due to heart failure without other known risk\n             factors for ARDS\n\n          -  Allergy or other contraindication to either budesonide and/or formoterol use\n\n          -  Expected hospital stay and/or survival <48 hours or admission for comfort or hospice\n             care\n\n          -  Patient, surrogate or physician not committed to full support (exception: a patient\n             will not be excluded if he/she would receive all supportive care except for attempts\n             at resuscitation from cardiac arrest)\n\n          -  Previous enrollment in this trial.\n\n          -  Co-enrollment with LIPS-A trial is not allowed.\n\n          -  An active enrollment in other concomitant trial will be judged on case by case basis\n             by PIs of both trials.\n\n          -  EKG and/or clinical presentation suggestive of acute coronary ischemia\n\n          -  New onset cardiac arrhythmia\n\n          -  Current atrial fibrillation with ventricular rate of >110/minute\n\n          -  Persistent sinus tachycardia of >130/minute despite early goal directed  therapy with\n             fluids, pressors, antibiotics and supplemental oxygen Pregnant patients"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01783821", 
            "org_study_id": "12-008192"
        }, 
        "intervention": [
            {
                "arm_group_label": "budesonide and formoterol", 
                "description": "Patients randomized to one of two intervention arms, will receive combined standard aerosolized doses of budesonide (0.5 mg) and formoterol (20 mcg) every 12 hours, for 5 days or until hospital discharge or death, with the first dose administered as soon as possible following randomization but not later than 4 hours.", 
                "intervention_name": "Budesonide and formoterol", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Budesonide", 
                "Formoterol"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Acute respiratory distress syndrome (ARDS)", 
        "lastchanged_date": "December 13, 2013", 
        "location": [
            {
                "contact": {
                    "email": "gcarr@deptofmed.arizona.edu", 
                    "last_name": "Gordon Carr, MD"
                }, 
                "contact_backup": {
                    "email": "herickso@email.arizona.edu", 
                    "last_name": "Heidi Erickson"
                }, 
                "facility": {
                    "address": {
                        "city": "Tucson", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85721"
                    }, 
                    "name": "University of Arizona"
                }, 
                "investigator": {
                    "last_name": "Gordon Carr, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "rvojnik@stanford.edu", 
                    "last_name": "Rosemary Vojnik"
                }, 
                "facility": {
                    "address": {
                        "city": "Stanford", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94305"
                    }, 
                    "name": "Stanford University"
                }, 
                "investigator": {
                    "last_name": "Joseph E Levitt, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "long.pamela@mayo.edu", 
                    "last_name": "Pamela Long, BSN", 
                    "phone": "904-953-7719"
                }, 
                "contact_backup": {
                    "email": "ruday.kellie@mayo.edu", 
                    "last_name": "Kellie Ruday, BS", 
                    "phone": "(904) 9537766"
                }, 
                "facility": {
                    "address": {
                        "city": "Jacksonville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32224"
                    }, 
                    "name": "Mayo Clinic in Florida"
                }, 
                "investigator": {
                    "last_name": "Emir Festic, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "vgoodspe@bidmc.harvard.edu", 
                    "last_name": "Valerie Goodspeed"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Beth Israel Medical Center"
                }, 
                "investigator": {
                    "last_name": "Daniel Talmor, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55905"
                    }, 
                    "name": "Mayo Clinic in Rochester"
                }, 
                "status": "Active, not recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "LIPS-B: Lung Injury Prevention Study With Budesonide and Beta Agonist (Formoterol)", 
        "overall_official": {
            "affiliation": "Mayo Clinic", 
            "last_name": "Emir Festic, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in oxygen saturation to fraction of inspired oxygen concentration (S/F) ratio", 
            "safety_issue": "No", 
            "time_frame": "Change in S/F ratio from baseline to day 5 after the first treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01783821"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mayo Clinic", 
            "investigator_full_name": "Emir Festic", 
            "investigator_title": "M.D.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Mayo Clinic", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Stanford University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Beth Israel Deaconess Medical Center", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of Arizona", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Mayo Clinic", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}